Earnings Call · Q4 FY2021·2022-03-10

Q4 21EPS -30.55%·Rev n/aQ3 21EPS -10.00%·Rev n/aQ2 21EPS 0.00%·Rev n/aQ1 21EPS +5.17%·Rev n/a⚠ consensus missing

TherapeuticsMD, Inc. TXMD

Disclaimer*

Lisa Wilson — Investor Relations

Hugh O’Dowd

James D’Arecca

Mark Glickman — Chief Commercial Officer

−27.5%1d on move date−27.0% vs SPY3d−32.5%5d−7.5%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TXMD calls or request research access.

More TXMD calls Browse calls Request research access